Myrigalone H (BioDeep_00000024366)

 

Secondary id: BioDeep_00000270569

human metabolite PANOMIX_OTCML-2023 natural product


代谢物信息卡片


1-(2,4-Dihydroxy-6-methoxy-3-methylphenyl)-3-phenyl-1-propanone

化学式: C17H18O4 (286.1205028)
中文名称:
谱图信息: 最多检出来源 Chinese Herbal Medicine(otcml) 4.44%

分子结构信息

SMILES: c1ccccc1CCC(=O)c1c(cc(c(c1O)C)O)OC
InChI: InChI=1S/C17H18O4/c1-11-14(19)10-15(21-2)16(17(11)20)13(18)9-8-12-6-4-3-5-7-12/h3-7,10,19-20H,8-9H2,1-2H3

描述信息

Myrigalone H is found in herbs and spices. Myrigalone H is a constituent of the fruit of Myrica gale (bog myrtle).
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics
Constituent of the fruit of Myrica gale (bog myrtle). Myrigalone H is found in herbs and spices.
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

同义名列表

24 个代谢物同义名

1-(2,4-Dihydroxy-6-methoxy-3-methylphenyl)-3-phenyl-1-propanone; 1-(2,4-dihydroxy-6-methoxy-3-methylphenyl)-3-phenylpropan-1-one; 2-(N-(Dicyclopropylmethyl)amino)oxazoline phosphate salt; N-(Dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine; N-(Dicyclopropylmethyl)-4,5-dihydro-2-oxazolamine; 4,5-dihydro-N-(Dicyclopropylmethyl)-2-oxazolamine; N-(Dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; 2,4-Dihydroxy-6-methoxy-3-methyldihydrochalcone; 1,1-Dicyclopropyl-N-(2-oxazolinyl)-methylamine; 2-((Dicyclopropylmethyl)imino)-oxazolidine; 2-((Dicyclopropylmethyl)amino)-2-oxazoline; 2-(N-(Dicyclopropylmethyl)amino)oxazoline; 2-((Dicyclopropylmethyl)imino)oxazolidine; 2-(dicyclopropylmethylamino)-2-Oxazoline; Oxaminozoline hemifumarate salt; Rilmenidine hemifumarate salt; Rilmenidene hemifumarate salt; Rilmenidine hemifumarate; Oxaminozoline; Rilmenidinum; Myrigalone H; Rilmenidine; Rilmenidene; Rilmenidia



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

14 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Andressa Manfredini, Larissa Constantino, Milton Castro Pinto, Monique Michels, Henrique Burger, Luiza W Kist, Milena Carvalho Silva, Lara Mezzari Gomes, Diogo Dominguini, Amanda Steckert, Carmen Simioni, Mauricio Bogo, Emílio Streck, Tatiana Barichello, João de Quevedo, Mervyn Singer, Cristiane Ritter, Felipe Dal-Pizzol. Mitochondrial dysfunction is associated with long-term cognitive impairment in an animal sepsis model. Clinical science (London, England : 1979). 2019 09; 133(18):1993-2004. doi: 10.1042/cs20190351. [PMID: 31527095]
  • Alessandro R Nascimento, Marcus V Machado, Fabiana Gomes, Aline B Vieira, Cassiano F Gonçalves-de-Albuquerque, Marcos A Lessa, Pascal Bousquet, Eduardo Tibiriçá. Central Sympathetic Modulation Reverses Microvascular Alterations in a Rat Model of High-Fat Diet-Induced Metabolic Syndrome. Microcirculation (New York, N.Y. : 1994). 2016 05; 23(4):320-9. doi: 10.1111/micc.12280. [PMID: 27086551]
  • Sam D Perez, Brooke Kozic, Christine A Molinaro, Srinivasan Thyagarajan, Mark Ghamsary, Cheri L Lubahn, Dianne Lorton, Denise L Bellinger. Chronically lowering sympathetic activity protects sympathetic nerves in spleens from aging F344 rats. Journal of neuroimmunology. 2012 Jun; 247(1-2):38-51. doi: 10.1016/j.jneuroim.2012.03.022. [PMID: 22546498]
  • Po-Sheng Yang, Hung-Tsung Wu, Hsien-Hui Chung, Chun-Ta Chen, Chin-Wen Chi, Ching-Hua Yeh, Juei-Tang Cheng. Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn-Schmiedeberg's archives of pharmacology. 2012 Jan; 385(1):51-6. doi: 10.1007/s00210-011-0691-1. [PMID: 21947253]
  • C-S Niu, H-T Wu, K-C Cheng, K-C Lin, C-T Chen, J-T Cheng. A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2011 Jun; 43(7):458-63. doi: 10.1055/s-0031-1275325. [PMID: 21484668]
  • Sandra L Burke, Roger G Evans, Geoffrey A Head. Effects of chronic sympatho-inhibition on renal excretory function in renovascular hypertension. Journal of hypertension. 2011 May; 29(5):945-52. doi: 10.1097/hjh.0b013e3283449529. [PMID: 21346623]
  • Lukáš Chytil, Josef Cvačka, Věra Marešová, Branislav Štrauch, Jiří Widimský, Martin Štícha, Ondřej Slanař. Development of a fast LC-MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS. Journal of mass spectrometry : JMS. 2010 Oct; 45(10):1179-85. doi: 10.1002/jms.1809. [PMID: 20815039]
  • S L Burke, R G Evans, G A Head. Effects of chronic sympatho-inhibition on reflex control of renal blood flow and plasma renin activity in renovascular hypertension. British journal of pharmacology. 2010 Jan; 159(2):438-48. doi: 10.1111/j.1476-5381.2009.00546.x. [PMID: 20015085]
  • Gerhard Groenewoud, Linda Potgieter, Bernhardt Meyer. Bioequivalence evaluation of rilmenidine in healthy volunteers. Arzneimittel-Forschung. 2009; 59(5):233-7. doi: 10.1055/s-0031-1296390. [PMID: 19537523]
  • Sandra L Burke, Goeffrey A Head. Cardiac and renal baroreflex control during stress in conscious renovascular hypertensive rabbits: effect of rilmenidine. Journal of hypertension. 2009 Jan; 27(1):132-41. doi: 10.1097/hjh.0b013e328317a7a7. [PMID: 19145779]
  • Isabelle L Signolet, Pascal P Bousquet, Laurent J P Monassier. Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits. American journal of hypertension. 2008 Jan; 21(1):54-60. doi: 10.1038/ajh.2007.9. [PMID: 18091744]
  • Candy K S Chan, Sandra L Burke, Geoffrey A Head. Contribution of imidazoline receptors and alpha2-adrenoceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine. Journal of hypertension. 2007 Jan; 25(1):147-55. doi: 10.1097/hjh.0b013e3280105ef0. [PMID: 17143186]
  • Jirí Widimský, Jana Sirotiaková. Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. Current medical research and opinion. 2006 Jul; 22(7):1287-94. doi: 10.1185/030079906x115577. [PMID: 16834827]
  • A O Konrady, Y R Kasherininov, A A Shavarov, E K Shavarova, N V Vachrameeva, A N Krutikov, E V Smirnova, E V Shlyakhto. How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. Journal of human hypertension. 2006 Jun; 20(6):398-406. doi: 10.1038/sj.jhh.1002004. [PMID: 16543910]
  • Kalina Kawecka-Jaszcz, Danuta Czarnecka, Marek Klocek, Michał Zabojszcz, Marta Kucharska, Rafał Jaworski, Robert Pachocki. Rilmenidine--its antihypertensive efficacy, safety and impact on quality of life in perimenopausal women with mild to moderate essential hypertension. Blood pressure. 2006; 15(1):51-8. doi: 10.1080/08037050600565969. [PMID: 16492616]
  • Peter Kotanko. Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood purification. 2006; 24(1):95-9. doi: 10.1159/000089444. [PMID: 16361848]
  • Rodney A Velliquette, Rachel Kossover, Stephen F Previs, Paul Ernsberger. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn-Schmiedeberg's archives of pharmacology. 2006 Jan; 372(4):300-12. doi: 10.1007/s00210-005-0024-3. [PMID: 16416266]
  • Łukasz Nowak, Marcin Adamczak, Andrzej Wiecek. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. American journal of hypertension. 2005 Nov; 18(11):1470-5. doi: 10.1016/j.amjhyper.2005.05.026. [PMID: 16280284]
  • Dmitrii A Anichkov, Nadezhda A Shostak, Olga V Schastnaya. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Current medical research and opinion. 2005 Jan; 21(1):113-9. doi: 10.1185/030079904x20277. [PMID: 15881482]
  • Murray Esler, Alan Lux, Garry Jennings, Jacqui Hastings, Flora Socratous, Gavin Lambert. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. Journal of hypertension. 2004 Aug; 22(8):1529-34. doi: 10.1097/01.hjh.0000125453.28861.b8. [PMID: 15257176]
  • M Esler, A Lux, G Jennings, J Hastings, F Socratous, G Lambert. [Rilmenidine sympatholytic activity preserves mental and orthostatic sympathetic response and epinephrine secretion]. Archives des maladies du coeur et des vaisseaux. 2004 Jul; 97(7-8):786-92. doi: . [PMID: 15506067]
  • Valentina Jovanovska, Eveline Eitle, Peter J Harris. Effects of rilmenidine on proximal tubular fluid absorption in rats. Clinical and experimental pharmacology & physiology. 2004 May; 31(5-6):348-53. doi: 10.1111/j.1440-1681.2004.04008.x. [PMID: 15191410]
  • Laurent Monassier, Hugues Greney, Lionel Thomas, Pascal Bousquet. Chronic treatment with rilmenidine in spontaneously hypertensive rats: differences between two schedules of administration. Journal of cardiovascular pharmacology. 2004 Mar; 43(3):394-401. doi: 10.1097/00005344-200403000-00010. [PMID: 15076223]
  • Geoffrey A Head, Sandra L Burke. Sympathetic responses to stress and rilmenidine in 2K1C rabbits: evidence of enhanced nonvascular effector mechanism. Hypertension (Dallas, Tex. : 1979). 2004 Mar; 43(3):636-42. doi: 10.1161/01.hyp.0000116301.02975.aa. [PMID: 14744928]
  • Peter A Meredith, John L Reid. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2004; 4(3):195-200. doi: 10.2165/00129784-200404030-00006. [PMID: 15134471]
  • Richard J Koletsky, Rodney A Velliquette, Paul Ernsberger. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Annals of the New York Academy of Sciences. 2003 Dec; 1009(?):251-61. doi: 10.1196/annals.1304.031. [PMID: 15028595]
  • D D Smyth, D Pirnat, B Forzley, S B Penner. Apparent absence of direct renal effect of imidazoline receptor agonists. Annals of the New York Academy of Sciences. 2003 Dec; 1009(?):288-95. doi: 10.1196/annals.1304.059. [PMID: 15028602]
  • Geoffrey A Head, Sandra L Burke. Are centrally acting imidazoline agents appropriate therapy for renovascular hypertension?. Annals of the New York Academy of Sciences. 2003 Dec; 1009(?):234-43. doi: 10.1196/annals.1304.029. [PMID: 15028593]
  • Peera Buranakitjaroen, Peerapong Kittipawong, Banhan Koanantakul, Chumpol Piamsomboon, Nattanun Prasassarakich, Songkwan Silaraks, Apichard Sukonthasarn, Assada Tiyapant. Efficacy and safety of rilmenidine, a selective imidazoline I1 receptor binding ligand, in mild-to-moderate Thai hypertensive patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2003 Oct; 86(10):903-10. doi: NULL. [PMID: 14650701]
  • Lale Koldas, Faruk Ayan, Baris Ikitimur. Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Japanese heart journal. 2003 Sep; 44(5):693-704. doi: 10.1536/jhj.44.693. [PMID: 14587651]
  • Anna Miczke, Danuta Pupek-Musialik, Maciej Cymerys, Wiesław Bryl, Magdalena Kujawska-Łuczak, Paweł Bogdański. [The effect of analysed hypotensive drugs on certain metabolic parameters]. Polskie Archiwum Medycyny Wewnetrznej. 2003 Mar; 109(3):237-42. doi: NULL. [PMID: 12924169]
  • Saco J de Visser, Jeroen-Paul van der Post, Loyd Nanhekhan, Rik C Schoemaker, Adam F Cohen, Joop M A van Gerven. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients. Clinical pharmacology and therapeutics. 2002 Oct; 72(4):419-28. doi: 10.1067/mcp.2002.127638. [PMID: 12386644]
  • A Remková, H Kratochvíl'ová. Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. Journal of human hypertension. 2002 Aug; 16(8):549-55. doi: 10.1038/sj.jhh.1001427. [PMID: 12149660]
  • J Widimský. [Efficacy and tolerance of rilmenidine in patients with mild to moderate hypertension. Results of a Czech and Slovak 6-month multicenter study]. Vnitrni lekarstvi. 2002 Aug; 48(8):724-9. doi: NULL. [PMID: 12425202]
  • Ben J A Janssen, Elena V Lukoshkova, Geoffrey A Head. Sympathetic modulation of renal blood flow by rilmenidine and captopril: central vs. peripheral effects. American journal of physiology. Renal physiology. 2002 Jan; 282(1):F113-23. doi: 10.1152/ajprenal.0153.2001. [PMID: 11739119]
  • Deni Pirnat, S Brian Penner, Donald D Smyth. Effects of rilmenidine and guanfacine in acute renal denervated rats. Proceedings of the Western Pharmacology Society. 2002; 45(?):15-7. doi: NULL. [PMID: 12434513]
  • J L Reid. Update on rilmenidine: clinical benefits. American journal of hypertension. 2001 Nov; 14(11 Pt 2):322S-324S. doi: 10.1016/s0895-7061(01)02239-7. [PMID: 11721891]
  • P Bousquet. I1 receptors, cardiovascular function, and metabolism. American journal of hypertension. 2001 Nov; 14(11 Pt 2):317S-321S. doi: 10.1016/s0895-7061(01)02238-5. [PMID: 11721890]
  • B Szabo, T Fritz, K Wedzony. Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex. British journal of pharmacology. 2001 Sep; 134(2):295-304. doi: 10.1038/sj.bjp.0704237. [PMID: 11564647]
  • S Schann, V Bruban, K Pompermayer, J Feldman, B Pfeiffer, P Renard, E Scalbert, P Bousquet, J D Ehrhardt. Synthesis and biological evaluation of pyrrolinic isosteres of rilmenidine. Discovery of cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-amine (LNP 509), an I1 imidazoline receptor selective ligand with hypotensive activity. Journal of medicinal chemistry. 2001 May; 44(10):1588-93. doi: 10.1021/jm001111b. [PMID: 11334568]
  • S J de Visser, J M van Gerven, R C Schoemaker, A F Cohen. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects. British journal of clinical pharmacology. 2001 May; 51(5):423-8. doi: 10.1046/j.1365-2125.2001.01387.x. [PMID: 11421999]
  • D N Mayorov, S L Burke, G A Head. Relative importance of rostral ventrolateral medulla in sympathoinhibitory action of rilmenidine in conscious and anesthetized rabbits. Journal of cardiovascular pharmacology. 2001 Mar; 37(3):252-61. doi: 10.1097/00005344-200103000-00003. [PMID: 11243415]
  • N De Luca, R Izzo, D Fontana, G Iovino, L Argenziano, C Vecchione, B Trimarco. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. Journal of hypertension. 2000 Oct; 18(10):1515-22. doi: 10.1097/00004872-200018100-00021. [PMID: 11057441]
  • G A Head, S L Burke. Comparison of renal sympathetic baroreflex effects of rilmenidine and alpha-methylnoradrenaline in the ventrolateral medulla of the rabbit. Journal of hypertension. 2000 Sep; 18(9):1263-76. doi: 10.1097/00004872-200018090-00013. [PMID: 10994758]
  • N R Robles. [Central agents in arterial hypertension: back to the future. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2000 Jul; 20(4):302-10. doi: NULL. [PMID: 11039256]
  • J L Reid. Rilmenidine: a clinical overview. American journal of hypertension. 2000 Jun; 13(6 Pt 2):106S-111S. doi: 10.1016/s0895-7061(00)00226-0. [PMID: 10921529]
  • B Bauduceau, H Mayaudon, O Dupuy. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril. Journal of cardiovascular risk. 2000 Feb; 7(1):57-61. doi: 10.1177/204748730000700110. [PMID: 10785875]
  • J P Fauvel, R Najem, B Ryon, M Ducher, M Laville. Effects of rilmenidine on stress-induced peak blood pressure and renal function. Journal of cardiovascular pharmacology. 1999 Jul; 34(1):41-5. doi: 10.1097/00005344-199907000-00007. [PMID: 10413065]
  • B Szabo, C Bock, U Nordheim, N Niederhoffer. Mechanism of the sympathoinhibition produced by the clonidine-like drugs rilmenidine and moxonidine. Annals of the New York Academy of Sciences. 1999 Jun; 881(?):253-64. doi: 10.1111/j.1749-6632.1999.tb09367.x. [PMID: 10415923]
  • P R King, A L Gundlach, W J Louis. Identification of imidazoline-receptor binding sites in cortex and medulla of the bovine adrenal gland. Colocalization with MAO-A and MAO-B. Annals of the New York Academy of Sciences. 1999 Jun; 881(?):161-70. doi: 10.1111/j.1749-6632.1999.tb09355.x. [PMID: 10415911]
  • L H Kudo, C A Hébert, A J Rouch. Inhibition of water permeability in the rat collecting duct: effect of imidazoline and alpha-2 compounds. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 1999 Jun; 221(2):136-46. doi: 10.1046/j.1525-1373.1999.d01-67.x. [PMID: 10352125]
  • C Bock, N Niederhoffer, B Szabo. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine. Naunyn-Schmiedeberg's archives of pharmacology. 1999 Apr; 359(4):262-71. doi: 10.1007/pl00005351. [PMID: 10344524]
  • M M El-Mas, A A Abdel-Rahman. Ethanol counteraction of I1-imidazoline but not alpha-2 adrenergic receptor-mediated reduction in vascular resistance in conscious spontaneously hypertensive rats. The Journal of pharmacology and experimental therapeutics. 1999 Feb; 288(2):455-62. doi: . [PMID: 9918545]
  • P R King, S Suzuki, A R Hosseini, D Iakovidis, T L Nero, G P Jackman, W J Louis, A L Gundlach. [3H]Rilmenidine-labelled imidazoline-receptor binding sites co-localize with [3H]2-(benzofuranyl)-2-imidazoline-labelled imidazoline-receptor binding sites and monoamine oxidase-B in rabbit, but not rat, kidney. Journal of the autonomic nervous system. 1998 Oct; 72(2-3):118-28. doi: 10.1016/s0165-1838(98)00096-4. [PMID: 9851560]
  • A R Hosseini, G P Jackman, P R King, W J Louis, A L Gundlach. Pharmacology and subcellular distribution of [3H]rilmenidine binding sites in rat brain. Journal of the autonomic nervous system. 1998 Oct; 72(2-3):129-36. doi: 10.1016/s0165-1838(98)00097-6. [PMID: 9851561]
  • M van den Buuse, S B Tritton, S L Burke, G A Head. Interaction of the dopamine D2 receptor agonist quinpirole with sympathetic vasomotor tone and the central action of rilmenidine in conscious rabbits. Journal of the autonomic nervous system. 1998 Oct; 72(2-3):187-94. doi: 10.1016/s0165-1838(98)00104-0. [PMID: 9851568]
  • S L Burke, S C Malpas, G A Head. Effect of rilmenidine on the cadiovascular responses to stress in the conscious rabbit. Journal of the autonomic nervous system. 1998 Oct; 72(2-3):177-86. doi: 10.1016/s0165-1838(98)00103-9. [PMID: 9851567]
  • G A Head, S L Burke, C K Chan. Site and receptors involved in the sympathoinhibitory actions of rilmenidine. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1998 Aug; 16(3):S7-12. doi: . [PMID: 9747904]
  • B Sözmen, C Kazaz, D Taşkiran, S Tüzün, E Y Sözmen. Effect of N-dicyclopropylmethyl-amino-2-oxazoline (S-3341) on antioxidant status and nitric oxide in hypertensive patients. Current medical research and opinion. 1998; 14(2):89-96. doi: 10.1185/03007999809113347. [PMID: 9704198]
  • B Szabo, R Urban. Role of I1 imidazoline receptors in the sympathoinhibition produced by intracisternally administered rilmenidine and moxonidine. Arzneimittel-Forschung. 1997 Sep; 47(9):1009-15. doi: . [PMID: 9342413]
  • G A Head, S L Burke, C K Chan. Central imidazoline receptors and centrally acting anti-hypertensive agents. Clinical and experimental hypertension (New York, N.Y. : 1993). 1997 Jul; 19(5-6):591-605. doi: 10.3109/10641969709083172. [PMID: 9247741]
  • D F Cechetto, R L Kline. Effect of rilmenidine on arterial pressure and urinary output in the spontaneously hypertensive rat. European journal of pharmacology. 1997 Apr; 325(1):47-55. doi: 10.1016/s0014-2999(97)00098-8. [PMID: 9151938]
  • R G Evans, A Shweta, S C Malpas, S M Fitzgerald, W P Anderson. Renal effects of rilmenidine in volume-loaded anaesthetized dogs. Clinical and experimental pharmacology & physiology. 1997 Jan; 24(1):64-7. doi: 10.1111/j.1440-1681.1997.tb01784.x. [PMID: 9043807]
  • S B Penner, D D Smyth. Renal denervation altered the hemodynamic and renal effects following intracerebroventricular administration of the I1-imidazoline receptor agonist, rilmenidine, in pentobarbital anaesthetized rats. Neurochemistry international. 1997 Jan; 30(1):55-62. doi: 10.1016/s0197-0186(96)00038-1. [PMID: 9116588]
  • M Scemama, B Février, I Beucler, F Dairou. [Effects of rilmenidine (hyperium) on lipid balance in hyperlipidemic hypertensive patients. Randomized, controlled, double-blind 8-week study vs. captopril in parallel groups]. Annales de cardiologie et d'angeiologie. 1996 Dec; 45(10):595-601. doi: . [PMID: 9033699]
  • T Zhang, E J Johns. Rilmenidine and reflex renal sympathetic nerve activation in Wistar and hypertensive rats. British journal of pharmacology. 1996 Nov; 119(6):1248-54. doi: 10.1111/j.1476-5381.1996.tb16029.x. [PMID: 8937730]
  • P A van Zwieten. New central mediators as targets of centrally acting antihypertensive drugs. Clinical and experimental hypertension (New York, N.Y. : 1993). 1996 Apr; 18(3-4):291-303. doi: 10.3109/10641969609088964. [PMID: 8743022]
  • P A van Zwieten. From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment. Journal of cardiovascular pharmacology. 1996; 27 Suppl 3(?):S5-10. doi: . [PMID: 8872294]
  • R G Evans, W P Anderson. Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors. British journal of pharmacology. 1995 Sep; 116(1):1557-70. doi: 10.1111/j.1476-5381.1995.tb16373.x. [PMID: 8564219]
  • J R Gregoire, S G Sheps. Newer antihypertensive drugs. Current opinion in cardiology. 1995 Sep; 10(5):445-9. doi: 10.1097/00001573-199509000-00002. [PMID: 7496051]
  • R Urban, B Szabo, K Starke. Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304. European journal of pharmacology. 1995 Aug; 282(1-3):29-37. doi: 10.1016/0014-2999(95)00265-m. [PMID: 7498287]
  • P R King, S Suzuki, W J Louis, A L Gundlach. Differential characteristics and localisation of [3H]oxazoline and [3H]imidazoline binding sites in rat kidney. European journal of pharmacology. 1995 Aug; 281(3):341-6. doi: 10.1016/0014-2999(95)00335-i. [PMID: 8521919]
  • B Szabo, R Urban. Mechanism of sympathoinhibition by imidazolines. Annals of the New York Academy of Sciences. 1995 Jul; 763(?):552-65. doi: 10.1111/j.1749-6632.1995.tb32449.x. [PMID: 7677373]
  • G A Head. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents. Annals of the New York Academy of Sciences. 1995 Jul; 763(?):531-40. doi: 10.1111/j.1749-6632.1995.tb32447.x. [PMID: 7677371]
  • P R King, S Suzuki, W J Louis, A L Gundlach. Distribution of nonadrenergic [3H]rilmenidine binding in rat brain and kidney. Annals of the New York Academy of Sciences. 1995 Jul; 763(?):194-207. doi: 10.1111/j.1749-6632.1995.tb32407.x. [PMID: 7677331]
  • S B Penner, D D Smyth. Rilmenidine alters renal function when administered intracerebroventricularly or intrarenally. Annals of the New York Academy of Sciences. 1995 Jul; 763(?):353-6. doi: 10.1111/j.1749-6632.1995.tb32422.x. [PMID: 7677346]
  • J H Laragh. Rilmenidine and the high risk hypertensive patient. Annals of the New York Academy of Sciences. 1995 Jul; 763(?):634-41. doi: 10.1111/j.1749-6632.1995.tb32458.x. [PMID: 7677383]
  • K Biyah, C Advenier. Effects of three alpha 2-adrenoceptor agonists, rilmenidine, UK 14304 and clonidine on bradykinin- and substance P-induced airway microvascular leakage in guinea-pigs. Neuropeptides. 1995 Apr; 28(4):197-207. doi: 10.1016/0143-4179(95)90023-3. [PMID: 7541119]
  • C Gargalidis-Moudanos, A Parini. Selectivity of rilmenidine for I1-imidazoline-binding sites in rabbit proximal tubule cells. Journal of cardiovascular pharmacology. 1995; 26 Suppl 2(?):S59-62. doi: . [PMID: 8642808]
  • B Trimarco, C Morisco, D Sarno, G Iovino, L Argenziano, R Russo, N De Luca, M Volpe. Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. Journal of cardiovascular pharmacology. 1995; 26 Suppl 2(?):S29-33. doi: NULL. [PMID: 8642802]
  • M Scemama, B Février, I Beucler, F Dairou. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. Journal of cardiovascular pharmacology. 1995; 26 Suppl 2(?):S34-9. doi: NULL. [PMID: 8642803]
  • D D Smyth, S B Penner. Renal I1-imidazoline receptor-selective compounds mediate natriuresis in the rat. Journal of cardiovascular pharmacology. 1995; 26 Suppl 2(?):S63-7. doi: NULL. [PMID: 8642809]
  • B Trimarco, G Rosiello, D Sarno, G Lorino, S Rubattu, N DeLuca, M Volpe. Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. The American journal of cardiology. 1994 Dec; 74(13):36A-42A. doi: 10.1016/0002-9149(94)90040-x. [PMID: 7998584]
  • M Aparicio, M Dratwa, N el Esper, J P Fillastre, B Levaltier, R Lins, A Meyrier, F Mignon, J P Ryckelynck, J Sennesael. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. The American journal of cardiology. 1994 Dec; 74(13):43A-50A. doi: 10.1016/0002-9149(94)90041-8. [PMID: 7998585]
  • W Pelemans, J Verhaeghe, G Creytens, G Coupez, A Van Dessel, M Opsomer, C Corcoran. Efficacy and safety of rilmenidine in elderly patients--comparison with hydrochlorothiazide. The Belgian Multicentre Study Group. The American journal of cardiology. 1994 Dec; 74(13):51A-57A. doi: 10.1016/0002-9149(94)90042-6. [PMID: 7998586]
  • R L Kline, J van der Mark, D F Cechetto. Natriuretic effect of rilmenidine in anesthetized rats. The American journal of cardiology. 1994 Dec; 74(13):20A-24A. doi: 10.1016/0002-9149(94)90037-x. [PMID: 7998580]
  • R Urban, B Szabo, K Starke. Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptors?. The Journal of pharmacology and experimental therapeutics. 1994 Aug; 270(2):572-8. doi: . [PMID: 7915315]
  • P Li, S B Penner, D D Smyth. Attenuated renal response to moxonidine and rilmenidine in one kidney-one clip hypertensive rats. British journal of pharmacology. 1994 May; 112(1):200-6. doi: 10.1111/j.1476-5381.1994.tb13052.x. [PMID: 8032642]
  • B Szabo, R Urban, K Starke. Sympathoinhibition by rilmenidine in conscious rabbits: involvement of alpha 2-adrenoceptors. Naunyn-Schmiedeberg's archives of pharmacology. 1993 Dec; 348(6):593-600. doi: 10.1007/bf00167235. [PMID: 7907776]
  • P R King, S Suzuki, T L Nero, A L Gundlach, W J Louis. Molecular studies of alpha-2-adrenoceptor and catecholamine-insensitive imidazoline-receptor binding sites using [3H]-rilmenidine in rat brain and kidney. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1993 Dec; 11(5):S160-1. doi: 10.1097/00004872-199312050-00059. [PMID: 7908962]
  • F Sannajust, G A Head. Effect of rilmenidine on baroreflex control of renal sympathetic nerve activity. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1993 Dec; 11(5):S328-9. doi: 10.1097/00004872-199312050-00143. [PMID: 7908964]
  • D N Maĭorov, M A Chernobel'skiĭ, O S Medvedev. [The effect of rilmenidine on the sympathetic activity of the renal nerve in waking barodenervated rats]. Eksperimental'naia i klinicheskaia farmakologiia. 1993 Nov; 56(6):19-21. doi: NULL. [PMID: 7906579]
  • C A Hamilton, E Jardine, J L Reid. Down-regulation of imidazoline sites in rabbit kidney. European journal of pharmacology. 1993 Oct; 243(1):95-7. doi: 10.1016/0014-2999(93)90174-g. [PMID: 7902815]
  • R L Kline, D F Cechetto. Renal effects of rilmenidine in anesthetized rats: importance of renal nerves. The Journal of pharmacology and experimental therapeutics. 1993 Sep; 266(3):1556-62. doi: NULL. [PMID: 8103796]
  • D Mayorov, M Chernobelski, O Medvedev. Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats. Journal of cardiovascular pharmacology. 1993 Aug; 22(2):314-20. doi: 10.1097/00005344-199308000-00022. [PMID: 7692175]
  • G Licata, R Scaglione, C Guillet, G Capuana, G Parrinello, A Indovina, R Lipari, G Mazzola, G Merlino. Double-blind controlled study of rilmenidine versus hydrochlorothiazide in mild hypertension: clinical and renal haemodynamic evaluation. Journal of human hypertension. 1993 Apr; 7(2):153-7. doi: NULL. [PMID: 8510088]
  • J Passeron, C Guillet. [Treatment with rilmenidine 1 mg per day: time-lag to maximum response. A multicenter ambulatory study. Le Groupe Français d'étude Multicentrique d'Hyperium]. Presse medicale (Paris, France : 1983). 1992 Dec; 21(43):2089-93. doi: NULL. [PMID: 1297118]
  • S Laurent, M Safar. Rilmenidine: a novel approach to first-line treatment of hypertension. American journal of hypertension. 1992 Apr; 5(4 Pt 2):99S-105S. doi: 10.1093/ajh/5.4.99s. [PMID: 1350733]
  • F Sannajust, C Barrès, E Koenig-Bérard, J Sassard. Sympathoinhibitory effects of rilmenidine may be mediated by sites located below the brainstem. British journal of pharmacology. 1992 Mar; 105(3):535-41. doi: 10.1111/j.1476-5381.1992.tb09015.x. [PMID: 1352718]